Figure 3 | Scientific Reports

Figure 3

From: First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants

Figure 3

ABS-VIR-001 is safe in animals based on a blood biomarker assessment. M-NSG mice were divided into 4 treatment groups as indicated and observed for body weights until D6. Then, the mice were euthanized, and blood was collected for hematological and metabolic evaluation. Overall, based on all the blood parameters evaluated, no major differences in were observed between ABS-VIR-001 treated mice and PBS control treated mice, indicating that ABS-VIR-001 is safe. (A) The quantitation of the mouse bodyweights over time following antibody treatment, represented by mean body weight per treatment group. B) Complete blood count (CBC) panel. (C) Blood differential (DIFF) panel. (D) Reticulocyte (RET) count. (E) Blood biochemistry panel. The graph was generated using the Prism (GraphPad) software v9.2.0 (https://www.graphpad.com/).

Back to article page